Hanmi制药公司揭幕了HM17321, 这是一种新的肥胖治疗, 刺激脂肪减退和瘦肌肉。 Hanmi Pharmaceuticals unveiled HM17321, a new obesity treatment that boosts fat loss and lean muscle.

Hanmi制药公司引进了HM17321, 这是一种新颖的肥胖治疗方法,它提倡减肥,同时增加瘦肌肉质量,解决当前GLP-1疗法的一个共同问题,可能导致肌肉丧失。 Hanmi Pharmaceuticals has introduced HM17321, a novel obesity treatment that promotes fat loss while enhancing lean muscle mass, addressing a common issue with current GLP-1 therapies that can lead to muscle loss. 针对CRF2受体,HM17321显示出作为一个具有成本效益的替代品的潜力,可以单独或与其他治疗一起用于改善减肥结果. Targeting the CRF2 receptor, HM17321 shows potential as a cost-effective alternative and can be used alone or with other treatments to improve weight loss outcomes. 药物的有前途的结果在2024年肥胖周会议上分享. The drug's promising results were shared at the 2024 ObesityWeek conference.